|
GRPEL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.87479999805385E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.19609999968706E-07 |
| Normal-vs-Stage2 |
2.671400E-01 |
| Normal-vs-Stage3 |
5.19789999930964E-09 |
| Normal-vs-Stage4 |
1.35450000104953E-08 |
| Stage1-vs-Stage2 |
7.957800E-03 |
| Stage1-vs-Stage3 |
1.445540E-02 |
| Stage1-vs-Stage4 |
3.161000E-03 |
| Stage2-vs-Stage3 |
1.578570E-04 |
| Stage2-vs-Stage4 |
2.25019999999798E-05 |
| Stage3-vs-Stage4 |
3.086400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.82540032773227E-10 |
| Normal-vs-AfricanAmerican |
3.811400E-04 |
| Normal-vs-Asian |
1.552370E-02 |
| Caucasian-vs-AfricanAmerican |
7.310600E-01 |
| Caucasian-vs-Asian |
1.633570E-02 |
| AfricanAmerican-vs-Asian |
8.431700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.85829999999854E-05 |
| Normal-vs-Female |
9.1428999926535E-09 |
| Male-vs-Female |
1.831980E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.43030000005129E-06 |
| Normal-vs-Age(41-60Yrs) |
3.74710000028422E-07 |
| Normal-vs-Age(61-80Yrs) |
8.63749999968633E-07 |
| Normal-vs-Age(81-100Yrs) |
1.609960E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.114800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.968400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.678000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.999800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.595200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.681800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.798310E-04 |
| Classical-VS-Follicular |
7.437000E-03 |
| Classical-VS-Other |
8.807400E-01 |
| Classical-VS-Normal |
1.19369999995733E-07 |
| Tall-VS-Follicular |
4.48390000018506E-07 |
| Tall-VS-Other |
2.831600E-01 |
| Tall-VS-Normal |
1.46620005025966E-09 |
| Follicular-VS-Other |
3.362600E-01 |
| Follicular-VS-Normal |
1.291780E-02 |
| Other-VS-Normal |
6.188400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63950999999551E-05 |
| Normal-vs-N1 |
2.4343999999954E-05 |
| N0-vs-N1 |
1.722160E-01 |
|
|
